布比卡因脂质体经外周神经阻滞在儿童下肢矫形术后的镇痛效果研究

注册号:

Registration number:

ChiCTR2600122919 

最近更新日期:

Date of Last Refreshed on:

2026-04-20 11:49:45 

注册时间:

Date of Registration:

2026-04-20 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

布比卡因脂质体经外周神经阻滞在儿童下肢矫形术后的镇痛效果研究

Public title:

Study on the analgesic effect of bupivacaine liposome transperitoneal nerve block after lower limb orthopedic surgery in children

注册题目简写:

English Acronym:

研究课题的正式科学名称:

布比卡因脂质体经外周神经阻滞在儿童下肢矫形术后的镇痛效果研究

Scientific title:

Study on the analgesic effect of bupivacaine liposome transperitoneal nerve block after lower limb orthopedic surgery in children

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

危思维 

研究负责人:

危思维 

Applicant:

Wei Siwei 

Study leader:

Wei Siwei 

申请注册联系人电话:

Applicant telephone:

+86 185 8885 7577

研究负责人电话:

Study leader's
telephone:

+86 185 8885 7577

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

wsw769850382@163.com

研究负责人电子邮件:

Study leader's E-mail:

wsw769850382@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国湖南省长沙市雨花区梓园路86号

研究负责人通讯地址:

中国湖南省长沙市雨花区梓园路86号

Applicant address:

No. 86, Ziyuan Road, Yuhaowan District, Changsha, Hunan, China

Study leader's address:

No. 86, Ziyuan Road, Yuhaowan District, Changsha, Hunan, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

湖南省儿童医院

Applicant's institution:

Hunan Children’ Hospital

研究负责人所在单位:

湖南省儿童医院

Affiliation of the Leader:

Hunan Children’ Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

HCHLL-2025-238

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

湖南省儿童医院伦理审查委员会

Name of the ethic committee:

Ethics Review Committee of Hunan Children's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2025-06-24 00:00:00

伦理委员会联系人:

秦红文

Contact Name of the ethic committee:

Qin Hongwen

伦理委员会联系地址:

中国湖南省长沙市雨花区梓园路86号

Contact Address of the ethic committee:

No. 86, Ziyuan Road, Yuhaowan District, Changsha, Hunan, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 731 8535 6014

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

湖南省儿童医院

Primary sponsor:

Hunan Children’ Hospital

研究实施负责(组长)单位地址:

中国湖南省长沙市雨花区梓园路86号

Primary sponsor's address:

No. 86, Ziyuan Road, Yuhaowan District, Changsha, Hunan, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

湖南

市(区县):

Country:

China

Province:

Hunan

City:

单位(医院):

湖南省儿童医院

具体地址:

中国湖南省长沙市雨花区梓园路86号

Institution
hospital:

Hunan Children’ Hospital

Address:

No. 86, Ziyuan Road, Yuhaowan District, Changsha, Hunan, China

经费或物资来源:

自筹

Source(s) of funding:

Self-financing

研究疾病:

儿童下肢矫形手术术后镇痛  

Target disease:

Analgesic effect after lower limb orthopedic surgery in children

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本项目旨在评估布比卡因脂质体经外周神经阻滞在儿童下肢大手术后的镇痛效果与安全性。小儿骨科下肢矫形术创伤性大、术后疼痛剧烈而持久,即使采用多模式镇痛,患儿对急性疼痛管理的满意度仍然较低,且在术后可能面临阿片类药物过量的风险,因此,寻找更为安全有效的镇痛方案至关重要。布比卡因脂质体作为一种新型长效局麻药,其缓释特性能够显著延长镇痛持续时间,提供更持久的镇痛效果。本研究采用随机对照试验设计,通过临床研究对比布比卡因脂质体与盐酸布比卡因,经外周神经阻滞对儿童下肢矫形术术后疼痛的影响,从而为这类手术寻找更好的术后镇痛方案和药物。  

Objectives of Study:

This project aims to evaluate the analgesic effect and safety of bupivacaine liposomes after major surgery for lower limbs in children. Pediatric orthopedic lower limb orthopedics is traumatic and has severe and long-lasting postoperative pain. Even with multimodal analgesia, children's satisfaction with acute pain management is still low and they may face the risk of opioid overdose after the operation. Therefore, it is crucial to find safer and more effective analgesic options. As a new long-acting local anesthetic, bupivacaine liposomes have a sustained release property that can significantly prolong the duration of analgesia and provide a more lasting analgesic effect. This study adopts a randomized controlled trial design, and through clinical studies, the effects of bupivacaine liposomes and bupivacaine hydrochloride, transsurface nerve block on postoperative pain in children's lower limb orthopedic surgery were compared, thereby finding better postoperative analgesia plans and drugs for this type of surgery.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1. 既往存在影响疼痛感知或麻醉效果的神经系统疾病,如癫痫;脊髓损伤;外周神经损伤等 2. 全身麻醉或神经阻滞禁忌症 3. 术前1月内使用阿片类药物;长期阿片类药物使用史(超过1月) 4. 不能遵从研究方案的精神或认知障碍患者 5. 对布比卡因脂质体或盐酸布比卡因过敏或有禁忌症的患者 6. 慢性疼痛病史 7. 术前评估存在严重合并症 8. 其他可能干扰研究结果的疾病 9. 术后转入ICU治疗者

Exclusion criteria:

1. There are previous neurological diseases that affect pain perception or anesthesia, such as epilepsy, spinal cord injury, peripheral nerve injury, etc 2. Contraindications of general anesthesia or nerve block 3. Use opioids within 1 month before the operation; long-term opioid use history (more than 1 month) 4. Patients with mental or cognitive impairment who cannot follow the study protocol 5. Patients who are allergic to bupivacaine liposomes or bupivacaine hydrochloride or contraindications 6. History of chronic pain 7. There are serious comorbidities in preoperative evaluation 8. Other diseases that may interfere with the study results 9. Those who were transferred to ICU treatment after surgery

研究实施时间:

Study execute time:

From 2025-11-30 00:00:00 To 2027-05-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-04-30 00:00:00 To 2027-04-30 00:00:00

干预措施:

Interventions:

组别:

盐酸布比卡因组

样本量:

105

Group:

Bupivacaine hydrochloride group

Sample size:

干预措施:

麻醉诱导后再超声引导下以0.25%盐酸布比卡因行外周神经阻滞,单次,剂量为5mg/kg,单次给药不超过300mg

干预措施代码:

Intervention:

After anesthesia induction, peripheral nerve block was performed under ultrasound guidance with 0.25% bupivacaine. A single dose of 5mg/kg was administered, and the total single dose should not exceed 300mg.

Intervention code:

组别:

布比卡因脂质体组

样本量:

105

Group:

Bupivacaine liposome group

Sample size:

干预措施:

麻醉诱导后再超声引导下以0.665%脂质体布比卡因脂质体行外周神经阻滞,单次,剂量为3mg/kg,单次给药不超过266mg

干预措施代码:

Intervention:

After anesthesia induction, peripheral nerve block was performed under ultrasound guidance with 0.665% liposomal bupivacaine liposomes. A single dose of 3mg/kg was administered, and the total single dose should not exceed 266mg.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

湖南 

市(区县):

长沙 

Country:

China

Province:

Hunan

City:

Changsha

单位(医院):

湖南省儿童医院 

单位级别:

三甲 

Institution
hospital:

Hunan Children’ Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

麻醉后72小时内的 NRS-AUC 疼痛评分

指标类型:

主要指标

Outcome:

NRS-AUC Pain Score within 72 hours after anesthesia

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后72小时内吗啡消耗当量

指标类型:

次要指标

Outcome:

Morphine consumption equivalent within 72 hours after surgery

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后72小时内的综合痛觉指数与阿片类药物消耗评分

指标类型:

次要指标

Outcome:

Comprehensive pain index and opioid consumption score within 72 hours of postoperative surgery

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后72小时内中至重度疼痛的发生率

指标类型:

次要指标

Outcome:

The incidence of moderate to severe pain within 72 hours after surgery

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

不良事件发生率

指标类型:

次要指标

Outcome:

Adverse Event Rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

no

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

no

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 6 years
最大 Max age 17 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

采用计算机生成的随机数字表将患者随机分为盐酸布比卡因组(B)和布比卡因脂质体组(LB)

Randomization Procedure (please state who generates the random number sequence and by what method):

The patients were randomly divided into bupivacaine hydrochloride group (B) and bupivacaine liposome group (LB) using a computer-generated random number table.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

除负责麻醉医生外,所有研究人员、患者、家长及评估者在整个研究期间均是设盲对象。在紧急情况下,可以请求揭盲治疗分配,该情况应被记录并分析以评估其与治疗的关联性。

Blinding:

Except for the anaesthesiologist, all researchers, patients, parents and evaluators were blinded throughout the study period. In an emergency, unblinding treatment allocation can be requested, which should be recorded and analyzed to evaluate its relevance to treatment.

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集主要为CRF表格

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data collection is mainly CRF tables

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2026-04-20 11:49:40